首页> 外文OA文献 >The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML)

【2h】

The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML)

机译：造血细胞移植（HCT）对生存的影响：对新诊断，高风险/二级AML（SAML）的老年患者CPX-351对7 + 3相的探索性分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tara L. Lin; Jorge E. Cortes; Laura F. Newell; Ellen K. Ritchie; Donna E. Hogge; Scott R. Solomon; Gary J. Schiller; Matthew J. Wieduwilt; Daniel H. Ryan; Robert J. Ryan; Arthur C. Louie;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML [J] . Lin Tara L., Cortes Jorge E., Newell Laura F., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：造血细胞移植对生存的影响：对新诊断，高风险/二次AML的老年患者CPX-351对7 + 3相的探索性分析
2. Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study [J] . Faderl Stefan, Cortes Jorge E., Ritchie Ellen K., Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：老年人的成果具有新诊断的，高风险/继发性敏感髓性白血病（AML），其达到CPX-351与7 + 3诱导的缓解：施算分析3阶段研究
3. Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States [J] . Kansal Anuraag, Reifsnider Odette, Todorova Lora, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：造血后细胞移植（HCT）存活对CPX-351与7 + 3的成本效益的影响在美国治疗相关的AML或AML-MRC的治疗
4. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses [O] . Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, 2021

机译：具有新诊断的高风险/二级AML的年龄较大的成年人达到CPX-351：第3阶段后HOC分析
5. Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7 + 3 Cytarabine and Daunorubicin [O] . Tara L. Lin, Geoffrey L. Uy, Matthew J. Wieduwilt, 2018

机译：二次急性髓性白血病（SAML）患者的细胞分析，其难治性贫血具有过量的转化中的爆炸（RAEB-T）纳入CPX-351与常规7 + 3个月曲和DaUnorubicin的第3阶段研究

The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML)

著录项

引文网络

相似文献

相关主题

期刊订阅